- Open Access
The costs associated with stroke care continuum: a systematic review
Health Economics Review volume 13, Article number: 32 (2023)
Stroke, a leading cause of death and long-term disability, has a considerable social and economic impact. It is imperative to investigate stroke-related costs. The main goal was to conduct a systematic literature review on the described costs associated with stroke care continuum to better understand the evolution of the economic burden and logistic challenges. This research used a systematic review method. We performed a search in PubMed/MEDLINE, ClinicalTrial.gov, Cochrane Reviews, and Google Scholar confined to publications from January 2012 to December 2021. Prices were adjusted using consumer price indices of the countries in the studies in the years the costs were incurred to 2021 Euros using the World Bank and purchasing power parity exchange rate in 2020 from the Organization for Economic Co-operation and Development with the XE Currency Data API. The inclusion criteria were all types of publications, including prospective cost studies, retrospective cost studies, database analyses, mathematical models, surveys, and cost-of-illness (COI) studies. Were excluded studies that (a) were not about stroke, (b) were editorials and commentaries, (c) were irrelevant after screening the title and abstract,(d) grey literature and non-academic studies, (e) reported cost indicators outside the scope of the review, (f) economic evaluations (i.e., cost-effectiveness or cost–benefit analyses); and (g) studies not meeting the population inclusion criteria. There may be risk of bias because the effects are dependent on the persons delivering the intervention. The results were synthetized by PRISMA method. A total of 724 potential abstracts were identified of which 25 articles were pulled for further investigation. The articles were classified into the following categories: 1)stroke primary prevention, 2) expenditures related to acute stroke care, 3) expenditures for post-acute strokes, and 4) global average stroke cost. The measured expenditures varied considerably among these studies with a global average cost from €610-€220,822.45. Given the great variability in the costs in different studies, we can conclude that we need to define a common system for assessing the costs of strokes. Possible limitations are related to clinical choices exposed to decision rules that trigger decisions alerts within stroke events in a clinical setting. This flowchart is based on the guidelines for acute ischemic stroke treatment but may not be applicable to all institutions.
Stroke is a leading cause of death and long-term disability and have a considerable social and economic impact as the second highest disease burden in Europe . A 34% increase of stroke is predicted in the coming decades, the number of ischemic strokes recorded in people above 80 years of age will triple (2010–2060), and an estimated 27% increase of stroke survivors will also increase expenditure on health and non-health care of stroke, which was 1.7% of overall health expenditure [2,3,4,5].
Most of the literature on stroke-related costs has focused on short-term , in-hospital expenditures  with a relative scarcity of studies  focused on long-term stroke-related components such as urban vs. non-urban territory, long-term ambulatory care, medical expenses, informal care, caregiver burden, events related to poor risk factors control, and social care services. Also, several authors have calculated projections of stroke for specific regions, countries [8,9,10,11,12], or internationally [13, 14], combining demographic projections with estimated future incidence and mortality rates or obtaining them by extrapolation from past trends [8,9,10, 12,13,14]. Therefore, there are great differences in the methods used for calculating costs, conditioned by the issues included as preventive costs of cardiovascular factors, especially hypertension (HTA) and atrial fibrillation (AF) [1, 15], the cost of new treatments such as thrombolysis and thrombectomy in early critical care (Code Stroke) [16, 17], and dependency management costs  after the episode; there are also differences in the calculated cost criteria [19,20,21] (direct vs. indirect) and in the final format of the result (total cost, average cost per stroke, average cost per person vs. mortality reduction benefits). Guidelines from different organizations are mostly similar and when differences exist, they are typically in the strength of the recommendation made about newly published data, with some guideline committees endorsing new protocols, whereas others require a higher level of data before making a strong recommendation . Consequently, there are significant differences among countries  regarding treatment accessibility and costs, and improvements and effective strategies would have a massive beneficial impact on healthcare systems . Also the complexities of finding the right balance between data privacy and access to data for health services research makes it difficult to compare the obtained data and the convergence in the calculation methods.
It is an imperative to investigate those new issues associated to stroke care economic burden and logistic challenges according the goal outlined by the Stroke Action Plan for Europe for the management of acute stroke that “every person with acute stroke deserves the right to have equal access to optimized and efficient stroke care, diagnosis and treatment, regardless of the place of living, age, gender, culture, social and economic status” .
The aim of this research is to conduct a systematic literature review on the described costs associated with stroke care continuum to better understand the evolution of the economic burden and logistic challenges.
The method used in this systematic review consisted of a search strategy, inclusion and exclusion criteria, data extraction, and quality assessments of included studies. The study was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guideline .
A comprehensive literature search was performed for full-text papers in the PubMed/MEDLINE, ClinicalTrial.gov, Cochrane Reviews , EconLit, and Ovid/EMBASE databases confined to publications in the last 10 years (January 1, 2012–December 31, 2021). We augmented the search by using Google Scholar and checking the references of the articles we obtained (Additional file 1: Appendix Table 1). Additional articles were added from systematic reviews using the snowball citation method. The systematic search was carried out in January–February 2022. The terms were matched with terms in the Medical Subject Heading(MeSH) database and included the possible combinations of stroke, atrial fibrillation, hypertension, cost analysis, economics, hospital charges, reimbursement, fees, cost-of-illness, social care charges, indirect costs, economic burden, informal caregiving, and dependency cost as [stroke and cost analysis] or [stroke and economics] or [stroke and hospital charges] or [stroke and social care charges] or [stroke and reimbursement] or [stroke and fees] or [stroke and cost-of-illness] or [stroke and indirect cost] or [stroke and economic burden] or [stroke and informal caregiving] or [stroke and dependency costs] or [cost and atrial fibrillation] or [stroke cost and atrial fibrillation] or [stroke cost and hypertension] or [stroke cost and blood pressure control] or [stroke cost and atrial fibrillation and hypertension].
Analysis and sources
We limited the search to titles and abstracts in a first approximation of human studies, published in English, and clinical trials or reviews. Subsequently, for the selected studies, search strategy development, searching, screening, application of criteria, selection, appraisal, data extraction, and synthesis were completed by at least two investigators. Disagreements were resolved by consensus. For study design and publication type, the inclusion criteria were all types of publications, including prospective cost studies, retrospective cost studies, database analyses, mathematical models, surveys, and cost-of-illness (COI) studies. The initial review of titles and abstracts excluded studies that (a) were not about stroke, (b) were editorials and commentaries, (c) were irrelevant after screening the title and abstract,(d) grey literature and non-academic studies, (e) reported cost indicators outside the scope of the review, (f) economic evaluations (i.e., cost-effectiveness or cost–benefit analyses); and (g) studies not meeting the population inclusion criteria.
According to previous evidence and the ESO Guideline Directory (mobile stroke units, acute stroke management, secondary prevention and rehabilitation, and long-term consequences) , four categories of costs were investigated: (1) effective preventive treatment to reduce the likelihood of people suffering strokes, such as risk factors associated with their incidence, especially AF and HTA, by primary care; (2) early critical care (Stroke Code) to minimize stroke damage and reduce the likelihood of disability by multi-disciplinary stroke units; (3) post-stroke care and after hospital discharge including secondary cardiovascular prevention and socio-health care at home or in a long-stay institution that estimates the value of all resources spent or foregone, including health care cost and productivity loss, due to stroke and the cost of caregiving by the replacement (RA) approach, also known as the proxy good method. Global cost-of-illness (COI) studies included both direct and indirect cost analyses . De-duplication strategy was applied by EndNote and Mendeley technics.
Analysis of direct cost
Costs related to the health care system: preventive care (AF and HTA), outpatient care, emergency care, hospital care, rehabilitation care, patient transportation inside the health system (ambulance, medical units), and pharmacological prescriptions. Standard medical care for strokes included early assessment, time-critical therapy, and stroke unit care. A cost for care provided by formal health care providers such as a home health aide is considered a direct cost.
Costs related to social care: the cost of residual disability after a stroke presents a major economic and humanistic burden and is not considered part of the care given by formal health care providers.
Informal care costs as well as non-medical costs outside the health system such as transfer of patients, informal care, or other expenses borne by the patient. The cost of informal caregiving is the value of the time spent by family members or other caregivers that is not considered part of the care given by formal health care providers. Non-medical costs outside the health system such as transport and time of patients and caregivers, assistive devices, or other expenses borne by the patient.
Analysis of indirect costs
Productivity costs: result from loss of paid and unpaid work and replacements due to premature death (mortality cost) and the cost of disability due to the reduced productivity of stroke survivors (morbidity cost).
The data analysis was carried out by collecting and synthesizing information on general study characteristics, methodology (study design, data sources, approaches, and calculated disease burden indicators), and estimated economic burdens (currency and year, cost components, cost perspective). Information collection was carried out by descriptively focusing on the burden of disease due to stroke at the household, health system, and community levels. Costs of healthcare will increase with forecasted inflation rates, so the current value of cost estimates should be adjusted. To compare costs of different countries in different study periods, we derived the current value in the article by using consumer price indices of the study countries in the years of the study and in 2021 from the World Bank and purchasing power parity (PPP) exchange rate in 2020 from the Organization for Economic Co-operation and Development (OECD) with the XE Currency Data API .
The Scottish Intercollegiate Guidelines Network (SIGN) grading system  checklist for systematic reviews was used to rank economic studies. The methodology behind the system is based on a set of variables that recognize key factors, especially bias and confounding variables, that can influence the quality of a study or its conclusion .
Figure 1 shows the Preferred Reporting for Systematic Reviews and Meta-Analysis (PRISMA) flowchart that summarizes the selected studies. A total of 724 potential abstracts were identified; 369 from MEDLINE via PubMed, 131 from Cochrane, and 224 from Google Academics. Of the 724 abstracts, 481 were excluded because they weren’t about strokes, 9 were excluded because they were editorials and commentaries, and 211 were excluded because they were obviously irrelevant after screening the title and abstract. We classified the 25 publications pulled for further investigation into four groups.
A summary of the studies according to stroke-related costs are described in Table 1.
Stroke primary prevention (Table 2)
Ninety percent of strokes are related to modifiable risk factors. Among them pointed out the AF and HTA [1, 8, 32] all both largely undiagnosed and uncontrolled. Most of the studies estimated treatment costs, but not the costs of its approach and control due to stroke events. The annual treatment of a patient with AF has an average cost between €4,750 and €23,064/patient/year . About one-third of these costs could be attributed to anticoagulation management . If cardiovascular complications are included , the average cost may increase to around €11,234/patient/year.
On the other hand, it is known that there is a direct relationship between HTA and risk of stroke and that its control reduces the risk of stroke . According to the studies in the review, the annual cost per patient with HTA is highly variable depending on the origin of the population studied and the therapy administrated [33, 34]. The range of the costs goes from €5 in patients who only receive dietary advice to more than €2,000/patient/year if they have pharmacological treatment [3, 36].
Acute care for a stroke (Table 3)
The average healthcare cost of a stroke per person, including early assessment, time-critical therapy, and stroke unit care, rehabilitation, and follow-up care, is estimated as an average of €5,798.15–€140,048 [20, 35, 48]. Regarding stroke types, Intracerebral Hemorrhage (ICH) was the most expensive, followed by Ischemic Stroke (IS), and Transient Ischemic Attack (TIA) [48, 49]. The Fig. 2 shows the flow-chart of the attending process from what have been calculated the cost issues.
Transfer to stroke care unit vs emergency department
It is of special interest due to the characteristics of non-urban and rural regions vs door-to-needle times. There are different ways: standard transfer to the closest local stroke center (in geographical areas where the default health authority assigned referral stroke center is a non-thrombectomy capable hospital where the individual may be treated with thrombolysis or standard medical care)vs Direct Transfer to Endovascular Center (a direct transfer of selected candidates to an endovascular center bypassing the nearest local hospital).This fact challenges the geographic equity in the access to thrombectomy. In both scenarios, time to treatment initiation is critical and the sooner the treatment is started, the higher are the chances of clinical recovery. The transfer could be made by standard medical transport or medicalized transfer-ground [cost €882.06 (661.24–1102.88), mobile stroke units (MSUs) [cost additional €86,174/year], and medicalized transfer-air [cost €9,042(6,781.58–11,303.30)] [38, 39, 50] according to local emergency medical services transport protocols.
Standard medical care in stroke includes early assessment, CT scan [€308.66 (231.8–385.52], time-critical therapy and emergency department visit [€913.78 (686.86–1,176.08)] 
Fibrinolysis [rt-PA(Activase)]used for improving neurologic recovery and reducing the incidence of disability in adults with acute IS. The average cost of rt-PA was €33,550.57 ± 17,308/patient 
Mechanical thrombectomy (MT): several studies have demonstrated the superiority of thrombolysis plus MT vs. thrombolysis alone to treat strokes [37, 52, 53]. The evidence demonstrates that performing MT up to 24 h after acute IS symptom onset is still cost-effective, suggesting that this intervention should be implemented based on improving quality of life as well as economic grounds resulting in a dominant therapy over rt-PA alone. Average cost of MT was €55,990.57 ± 23,321. Thrombectomy was associated with an increase in initial hospital cost of €22,440/patient compared with rt-PA alone .
The acute costs of stroke were variable according to the type of stroke suffered, as well as the treatment performed. The costs are different if the patient receives standard or conservative treatment, or an interventional treatment. In the case of intracerebral hemorrhage, by the severity and comorbidities frequently associates, have a highest burden by treatment, rehabilitation and support services. The average costs range from €45,500.71–73,367.55/patient . Many organizations, such as the European Stroke Organization and The Stroke Alliance for Europe, have prioritized primary prevention for this disease .
The mean total cost per patient for the management of acute stroke was €13,138.97. The hospital stays (€5,916.62) and rehabilitation (€3,835.40) were the resources that contributed the most to this total cost .
Post-acute stroke (Table 4)
The two main factors that determine spending in the first year are hospitalizations and convalescence/rehabilitation. Hospitalizations accounted for 45% of the difference in spending between the first year after the stroke and the year before, while convalescence/rehabilitation accounted for 33% .
Rehabilitation is very important to reduce mortality. It used to be done by a multidisciplinary team . Patients with greater disability (Rankin 3–5: 41.8%) have a higher cost than patients without disability (Rankin 0–2: 20.8%), or €8,500 vs. €6,000 . There is large variability in access to rehabilitation depending on the different sanitary systems. The first-year post-stroke costs are €29,484 on average. For the third year and onward, follow-up cost equal to cost of the second year, but rehabilitation remains a major part of the cost [40, 41]. Europe-wide implementation of home-based rehabilitation was estimated to be cost-effective (> 90%) compared to center-based rehabilitation  but the domiciliary service was found to cost 2.6 times more.
Secondary cardiovascular prevention
23% of patients who has suffered a stroke will suffer a second stroke with more disability (36% to 51%) and increased mortality (20% to 34%). Secondary prevention measures have the potential to reduce the number of stroke survivors having additional strokes by 80% . Most factors are modifiable, and stroke risk prediction with machine learning techniques (MLT) has a significant ability to predict the risk of stroke occurrence, so it highlights the potential value of expanding the use of MLT in clinical practice. Nowadays, only 40% of patients with HTA after a stroke were correctly treated, and there are many patients with AF that don’t receive Oral anticoagulant Therapy (OAT). In the review period, there is no information about the cost of the prevention of a new stroke and/or the cardiovascular factors related to.
Socio-sanitary (formal care)
Up to 50% of survivors were chronically disabled [18, 45]. Most stroke survivors return from the hospital to community or residential care settings where many receive help with activities of daily living (ADLs) and instrumental activities of daily living (IADLs). The range of costs varied from €6,490.80 to €31,436.72/patient/year  statistically significant differences in the cost of formal care were found according to patients’ degrees of dependency and depending on whether all elderly stroke survivors were considered or only those with stroke-related health problems.
Non-healthcare system costs
Social care costs
Non-medical costs outside the healthcare system such as accompaniment to physician appointments, transportation, assistive devices, or other expenses borne by the patient. Residual disability after a stroke presents a major economic and humanistic burden. The interval cost is between €3,165–29,484/patient/year [42, 43, 58].
Patients’ and caregivers’ informal care costs
An estimated average of time-care provided by friends or family (who would have provided the same type of caregiving services)with an average cost €10,508/patient/year [42, 43, 58].
Include the loss of paid and unpaid work and replacements due to premature death (mortality cost) and the cost of disability because of the reduced productivity of stroke survivors (morbidity cost) associated with the replacement of workers including productivity losses due to the substitution of workers or the training costs of new employees. This has a range of cost between €276 and €8,336/patient/year .
Global average stroke cost (Table 5)
Table 5 presents a summary of studies reporting global average costs of stroke in the long term (more than 30 days post-stroke). Many these studies were retrospective analyses of a sample of Medicare patients hospitalized for ischemic stroke. The measured expenditures varied considerably among these studies with an average cost from €610-€220,822.45/patient. Seventy-four percent of the costs in the first year post-stroke was in the first six months . Average per patient per year costs is greater in high-income countries.
Costs vary considerably between patients in the first five years post-stroke. They are highest in patients with ICH, older patients, and those with more severe strokes. Over time the costs of providing social care account for a greater proportion of the total care costs of stroke. Prevention transfer pre-hospital services, thrombolysis, thrombectomy and early supported discharge services are cost-effective and cost-saving, with economic savings to healthcare and social care costs of stroke [3, 46].
Most cost-analysis studies conducted thus far have focused on short-term, in-hospital costs of a stroke. Most of these studies are retrospective analyses of different inpatient care databases, and due to diversity in reporting, a detailed cost analysis addressing different segments of services was not possible. Therefore, there is a need for in-depth research using large databases . Stroke incidence is set to increase by 32% in 2035 and 41% in 2040 in addition to long-term disability among stroke survivors . Updated treatment guidelines and improved detection of strokes remain the cornerstone .
Stroke primary prevention
Only primary care performance in stroke care is associated with lower hospital costs  but despite the progress in AF diagnosis and management, prevention of strokes remains the cornerstone. The clinical benefits of appropriate anticoagulation are widely recognized, and clinicians should be aware of the importance of anticoagulation therapies in stroke prophylaxis, the occurrence of stroke, and the downstream economic burden on an increasingly aging population . AF quintuples the risk of stroke. Ischemic stroke occurring in patients with AF ≥ 75 year-old was 2.3 times higher and one-fourth ≥ 80 year-old will suffer an AF . The 23.5% with known AF were not receiving OAT. The AF was associated with more severity, disability and 20% increase in stroke-related costs .
Recently  Cardiology Associations have proposed adding the costs, both in healthcare resources and in social burden, due to stroke events associated with poor control of anticoagulants in AF, which would increase the mean costs significantly. It must be added to overall cost of stroke, €295/year/patient with atrial fibrillation and not-treating and/or inappropriate anticoagulation treatment.
Regarding HTA, the estimation in the overall population of the costs per mmHg reduction does not seem to be a comparable methodology given the difficulty of having reference values and, especially, the variability in blood pressure measurements, treated or not. Therefore, the cost estimate provided by the different studies is neither homogeneous nor does it include all the possible factors and, therefore, its results would be difficult to generalize. Each risk factor would modify the complexity in cost estimation and the future seems to be associated with the development of machine learning techniques to assess the effect severity and unmeasured confounding.
Acute stroke care
The long-term severity and progression of cerebral infarction before and after recanalization is modified by triage strategy and prehospital pathways, and these have not been evaluated enough for complexity and accessibility. The cost can vary significantly by clinical  and geographic factors. However, there were no significant cost differences between direct admission and secondary transfer (€214.55- 781.30) . Among the publications that focused on direct costs, there was a greater emphasis on emergency and short-term care, and less on preventive care (AF and HTA as factors related to stroke incidence), outpatient, rehabilitation, and nursing home care. The greatest determinants of costs in year one was hospitalization, representing 48.5% of the overall costs .
Given that the published data confirmed that thrombectomy-treated patients were significantly more likely to be functionally independent than those receiving standard care, early critical care has become a keystone of acute ischemic stroke therapy, but also accounted for nearly one-third of the total expenditure [58, 67,68,69,70,71]. The costs of selection for Endovascular thrombectomy (EVT) have rarely been studied [69, 70] beyond interventions representing costs made in consecutive years post-stroke. Every 10 min of earlier treatment by pre-hospital triage and in-hospital workflow to endovascular thrombectomy may be €11,968.93 (€6,9589.47–18,027.94) of net monetary benefits for taking health care and societal perspectives over a disability-free life  . Consequently, health care policies to implement efficient pre-hospital triage and accelerate in-hospital work-flow are needed.
Of the patients who have a stroke, 26.3% will need a caregiver, but the costs are higher in the first year due to the expense of hospital admission and rehabilitation, which represent 33% of the costs. After year one, the increase in expenditure seems mainly determined by additional hospital admissions and drug treatment, [17, 71] but new data  showed that the increase in the economic burden (health and social costs) is mainly associated with social care (300%) after one year post-stroke (€10,204.9–€31,964.9/patient/year) and up to five years post-stroke vs. a mean health cost increase (€15,728.9–€20,994.2/patient/year).
Comprehensive rehabilitation and personalized care and support for as long as the person may need should be possible. However, it has been shown that  the number of hours of help received by stroke survivors is higher than in prior studies. Under base case assumptions, home-based rehabilitation was found highly likely to be cost-effective (> 90%) compared to center-based rehabilitation in most European countries .
Global average stroke cost
The total costs varied significantly as a result of the heterogeneous cost variables described . In Europe the most common cause of death is morbidity and associated disability . The main forms of CVD are ischemic heart disease (IHD) and stroke . Stroke mortality has been declining since the early twentieth century.
The total costs of strokes in 2017 in Europe were €60 billion ; 62% of the costs were for inpatient hospital care, 18% for outpatient care, 13% for primary care, 5% for pharmaceuticals, 3% for emergency care, and 8% more were spent on social care systems. As of now, approximately 34% of the global total healthcare expenditure is spent on stroke . These costs are especially high in older patients, in patients with greater severity, and those with hemorrhagic stroke. Patients with early thrombolysis or early rehabilitation reduced their health and social care costs by five years after stroke. Figure 2 shows the global stroke cost obtained from the results of the studies included in the current review.
Few studies have considered the indirect costs of stroke, including productivity loss due to morbidity and mortality, and costs of patients and caregivers usually provided by unpaid family members, although the indirect costs have been claimed to be large. It has been found that productivity cost estimates vary remarkably according to the choice of method in many disabling diseases such as stroke, and the results of monetary amounts are disease-specific, as seen when comparing the productivity costs in different stroke subtypes. The methodology for estimating lost productivity is an area of considerable debate. Existing literature regarding the economic burden of stroke is concentrated in high-income settings. There are necessary adjustments, especially related to vacancy durations and macroeconomic conditions, and we encourage future studies to make use of routine data to generate more accurate productivity estimates for strokes.
In the Stroke Action Plan for Europe a goal was outlined for the management of acute stroke that “every person with acute stroke deserves the right to have equal access to optimized and efficient stroke care, diagnosis and treatment, regardless of the place of living, age, gender, culture, social and economic status” , but the inclusion of adjustment costs may produce a more stringent cost-effectiveness analysis criterion, may affect the relative priority of interventions, and make consensus impossible even on ordinal rankings of health states . Further studies are required to quantify the cost-effectiveness or cost savings of these interventions independently and when combined in regional strategies and community networks of stroke care.
There is a wide interval in the information on the global costs of strokes with an average between €610-€220,822.45 based on the cost of the illness.
There is high variability in the relative percentage of costs related to each evolutionary stage of stroke: primary prevention (8.8%), acute stroke (31.67%), and post-stroke (49.4%).
The greatest determinant of cost was inpatient hospital care, representing 44.49% of overall costs, but the increase in the economic burden (health and social care costs) is mainly associated with social care (300%) after one year post-stroke.
Given the great variability in costs in the different studies, it would be convenient to define a common schedule for assessing the stroke costs to obtain comparable results. This variability may be related to differences among cost factors included, the monetary value, the offered services included in each health system, and the complexity of access to data from health services.
Availability of data and materials
Medical Subject Heading
Purchasing Power Parity
Organization for Economic Co-operation and Development
Scottish Intercollegiate Guidelines Network
Preferred Reporting for Systematic Reviews and Meta-Analysis
Direct Oral Anti-Coagulants
Vitamin K Antagonists
Transient Ischemic Attack
Stent Retriever Thrombectomy
Tissue-type Plasminogen Activator
Mobile Stroke Unit
Stroke Cohort Out-comes of Rehabilitation
National Health and Aging Trends Study
Machine Learning Techniques
Oral Anticoagulant Therapy
Activities of Daily Living
Quality of Life
Ischemic Heart Disease
The World Health Organization. Global Burden of Stroke. https://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf. (Accessed 30 July 2021)
Luengo-Fernandez R, Violato M, Candio P, Leal J. Economic burden of stroke across Europe: a population-based cost analysis. Eur Stroke J. 2020;5(1):17–25. https://doi.org/10.1177/2396987319883160.
Joo H, George MG, Fang J, Wang G. A literature review of indirect costs associated with stroke. J Stroke Cerebrovasc Dis. 2014;23(7):1753–63. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.02.017.
Benjamin EJ, Muntner P, Alonso A, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56. https://doi.org/10.1161/CIR.0000000000000659. e528.
Dewilde S, Annemans L, Pincé H, Thijs V. Hospital financing of ischaemic stroke:determinants of funding and usefulness of DRG subcategories based on severity of illness. BMC Health Serv Res. 2018;18(1):356. https://doi.org/10.1186/s12913-018-3134-6.
Rai AT, Evans K, Riggs JE, Hobbs GR. Intravenous thrombolysis of large vessel occlusions is associated with higher hospital costs than small vessel strokes: a rationale for developing stroke severity-based financial models. J NeuroInterv Surg. 2016;8(4):423–8. https://doi.org/10.1136/neurintsurg-2014-011632.
Lahr MMH, van der Zee DJ, Luijckx GJ, Vroomen PCAJ, Buskens E. Centralising and optimising decentralised stroke care systems: a simulation study on short-term costs and effects. BMC Med Res Methodol. 2017;17(1):1–2. https://doi.org/10.1186/s12874-016-0275-3.
Foerch C, Misselwitz B, Sitzer M, Steinmetz H, Neumann-Haefelin T. The projected burden of stroke in the German federal state of Hesse up to the year 2050. Dtsch Ärztebl Int. 2008;105:467–73. https://doi.org/10.3238/arztebl.2008.0467.
Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Modeling the future burden of stroke in The Netherlands: impact of aging, smoking, and hypertension. Stroke. 2005;36:1648–55. https://doi.org/10.1161/01.STR.0000173221.37568.d2.
Sivenius J, Torppa J, Tuomilehto J, et al. Modelling the burden of stroke in Finland until 2030. Int J Stroke. 2009;4:340–5. https://doi.org/10.1111/j.1747-4949.2009.00330.x.
Smith S, Horgan F, Sexton E, et al. The future cost of stroke in Ireland: an analysis of the potential impact of demographic change and implementation of evidence-based therapies. Age Ageing. 2013;42:299–306. https://doi.org/10.1093/ageing/afs192.
Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke. 2006;37:1179–83. https://doi.org/10.1161/01.STR.0000217450.21310.90.
Hallström B, Jönsson AC, Nerbrand C, Norrving B, Lindgren A. Stroke incidence and survival in the beginning of the 21st century in southern Sweden: comparisons with the late 20th century and projections into the future. Stroke. 2008;39:10–5. https://doi.org/10.1161/STROKEAHA.107.491779.
Truelsen T, Piechowski-Jóźwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol. 2006;13:581–98. https://doi.org/10.1111/j.1468-1331.2006.01138.x.
European Stroke Organization, Stroke Alliance for Europe. Stroke action plan for Europe 2018–2030. https://www.safestroke.eu/wp-content/uploads/2019/05/SAFE-SAPE-ebook-correct-version_compressed-FINAL-FINAL.pdf. (Accessed 10 July 2019)
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89. https://doi.org/10.1186/s13643-021-01626-4.
Simpson AN, Bonilha HS, Kazley AS, Zoller JS, Simpson KN, Ellis C. Impact of outpatient rehabilitation medicare reimbursement caps on utilization and cost of rehabilitation care after ischemic stroke: Do caps contain costs? Arch Phys Med Rehabil. 2015;96(11):1959–65. https://doi.org/10.1016/j.apmr.2015.07.008.
Queralt-Tomas L, Clua-Espuny JL, Fernández-Saez J, et al. Risk of dependency: a challenge for health and social care planning-observational stroke cohort. Value Health. 2019;22(10):1083–91. https://doi.org/10.1016/j.jval.2019.05.009.
Chabra M, Sharma A, Ajay KR, Rathore MS. Assessment of risk factors, cost of treatment, and therapy outcome in stroke patients: evidence from cross-sectional study. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):575–80. https://doi.org/10.1080/14737167.2019.1580574.
Abdo RR, Abboud HM, Salameh PG, Jomaa NA, Rizk RG, Hosseini HH. Direct medical cost of hospitalization for acute stroke in Lebanon: a prospective incidence-based multicenter cost-of-illness study. J Health Care Organ Prov Financ. 2018;55:1–11. https://doi.org/10.1177/0046958018792975.
Kunz WG, Hunink MG, Dimitriadis K, et al. Cost-effectiveness of endovascular therapy for acute ischemic stroke: a systematic review of the impact of patient age. Radiology. 2018;288(2):518–26. https://doi.org/10.1148/radiol.2018172886.
Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. 2020;368:l6983. https://doi.org/10.1136/bmj.l6983.
Wafa HA, Wolfe CDA, Emmett E, Roth GA, Johnson CO, Wang Y. Burden of stroke in Europe: thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years. Stroke. 2020;51(8):2418–27. https://doi.org/10.1161/STROKEAHA.120.029606.
Chalmers I. The cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci. 1993;703:156–65.
European Stroke Organisation. ESO Guideline Directory - Guidelines. https://eso-stroke.org. (Accessed 26 July 2022)
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. New York: Oxford University Press; 2015.
XE. Historical rate tables. https://www.xe.com/es/currencytables/. (Accessed 17 Mar 2022)
Baker A, Young K, Potter J, Madan I. A review of grading systems for evidence-based guidelines produced by medical specialties. Clin Med. 2010;10(4):358–63. https://doi.org/10.7861/clinmedicine.10-4-358.PMID:20849010;PMCID:PMC4952165.
Salvatore FP, Spada A, Fortunato F, Vrontis D, Fiore M. Identification of health expenditures determinants: a model to manage the economic burden of cardiovascular disease. Int J Environ Res Public Health. 2021;18(9):4652. https://doi.org/10.3390/ijerph18094652.PMID:33925630;PMCID:PMC8124329.
Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health. 2012;15:240–8.
Cotté FE, Chaize G, Gaudin AF, Samson A, Vainchtock A, Fauchier L. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace. 2016;18(4):501–7. https://doi.org/10.1093/europace/euv248.PMID:26718532;PMCID:PMC4865060.
López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359: j5058.
Giner-Soriano M, Casajuana M, Roso-Llorach A, et al. Efectividad, seguridad y costes de la prevención tromboembólica en fibrilación auricular Estudio de cohortes apareado por Propensity score. Aten Primaria. 2020;52(3):176–84.
Zhang D, et al. A systematic review of economic evidence on community hypertension interventions. Am J Prev Med. 2017;53(6 Supplement 2):S121–30. https://doi.org/10.1016/j.amepre.2017.05.008.
Gheorghe A, Griffiths U, Murphy A, et al. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018;18:975. https://doi.org/10.1186/s12889-018-5806-x.
Kostova D, Spencer G, Moran AE, et al. The cost-effectiveness of hypertension management in low-income and middle-income countries: a review. BMJ Global Health. 2020;5(9):e002213. https://doi.org/10.1136/bmjgh-2019-002213. PMID: 32912853; PMCID: PMC7484861.
Shireman TI, Wang K, Saver JL, et al. Cost-effectiveness of solitaire stent retriever thrombectomy for acute ischemic stroke: results from the SWIFT-PRIME trial (solitaire with the intention for thrombectomy as primary endovascular treatment for acute ischemic stroke). Stroke. 2017;48(2):379–87. https://doi.org/10.1161/STROKEAHA.116.014735.
Zhang H, Yin Y, Zhang C, et al. Costs of hospitalization for stroke from two urban health insurance claims data in Guangzhou City, southern China. BMC Health Serv Res. 2019;19:671. https://doi.org/10.1186/s12913-019-4530-2.
Reimer AP, Zafar A, Hustey FM, Kralovic D, Russman AN, Uchino K, Hussain MS, Udeh BL. Cost-Consequence Analysis of Mobile Stroke Units vs. Standard Prehospital Care and Transport. Front Neurol. 2020;10:1422. https://doi.org/10.3389/fneur.2019.01422.
de Andrés- F, Vivancos Mora J, Barriga Hernández FJ, et al. Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: The CODICE Study. Neurologia. 2015;30(9):536–44. https://doi.org/10.1016/j.nrl.2014.06.002.
Van Meijeren-Pont W, Tamminga SJ, Goossens PH, Groeneveld IF, Arwert H, Meesters JJL, Mishre RR, Vlieland TPM, van den Hout WB, The Stroke Cohort Outcomes of REhabilitation (SCORE) study group. Societal burden of stroke rehabilitation: Costs and health outcomes after admission to stroke rehabilitation. J Rehabil Med. 2021;53(6):jrm00201. https://doi.org/10.2340/16501977-2829.
Oliva-Moreno J, Aranda-Reneo I, Vilaplana-Prieto C, González-Domínguez A, Hidalgo-Vega A. Economic valuation of informal care in cerebrovascular accident survivors in Spain. BMC Health Serv Res. 2013;13:508. https://doi.org/10.1186/1472-6963-13-508.
Skolarus LE, Freedman VA, Feng C, Wing JJ, Burke JF. Care received by elderly US stroke survivors may be underestimated. Stroke. 2016;47(8):2090–5. https://doi.org/10.1161/STROKEAHA.116.012704.
Alvarez-Sabín J, Quintana M, Masjuan J, et al. Economic impact of patients admitted to stroke units in Spain. Eur J Health Econ. 2017;18(4):449–58. https://doi.org/10.1007/s10198-016-0799-9.
Van Eeden M, van Heugten C, van Mastrigt GA, van Mierlo M, Visser-Meily JM, Evers SM. The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke. BMJ Open. 2015;5(11):e008220. https://doi.org/10.1136/bmjopen-2015-008220.
Xu XM, Vestesson E, Paley L, et al. The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke. Eur Stroke J. 2018;3(1):82–91. https://doi.org/10.1177/2396987317746516.
Patel A, Berdunov V, Quayyum Z, King D, Knapp M, Wittenberg R. Estimated societal costs of stroke in the UK based on a discrete event simulation. Age Ageing. 2020;49(2):270–6. https://doi.org/10.1093/ageing/afz162.
Rochmah TN, Rahmawati IT, Dahlui M, Budiarto W, Bilqis N. Economic burden of stroke disease: a systematic review. Int J Environ Res Public Health. 2021;18(14):7552. https://doi.org/10.3390/ijerph18147552.
Strilciuc S, Grad DA, Radu C, Chira D, Stan A, Ungureanu M, Gheorghe A, Muresanu FD. The economic burden of stroke: a systematic review of cost of illness studies. J Med Life. 2021;14(5):606–19. https://doi.org/10.25122/jml-2021-0361.
Kim J, Easton D, Zhao H, et al. Economic evaluation of the Melbourne mobile stroke unit. Int J Stroke. 2021;16(4):466–75.
Diringer MN, Edwards DF, Mattson DT, et al. Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke. 1999;30(4):724–8. https://doi.org/10.1161/01.str.30.4.724.
Peultier AC, Pandya A, Sharma R, Severens JL, Redekop WK. Cost-effectiveness of mechanical thrombectomy more than 6 hours after symptom onset among patients with acute ischemic stroke. JAMA Network Open. 2020;3(8):e2012476. https://doi.org/10.1001/jamanetworkopen.2020.12476.
Lenz-Alcayaga R, Paredes-Fernández D, Hernández-Sánchez K, Valencia-Zapata JE. Cost-utility analysis: Mechanical thrombectomy plus thrombolysis in ischemic stroke due to large vessel occlusion in the public sector in Chile. Medwave. 2021;21(3):e8152. https://doi.org/10.5867/medwave.2021.03.8152.
Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group Neurology. 1998;50(4):883–90. https://doi.org/10.1212/wnl.50.4.883.
Hansen BM, Nilsson OG, Anderson H, Norrving B, Säveland H, Lindgren A. Long term (13 years) prognosis after primary intracerebral haemorrhage: a prospective population based study of long term mortality, prognostic factors and causes of death. J Neurol Neurosurg Psychiatry. 2013;84(10):1150–5. https://doi.org/10.1136/jnnp-2013-305200.
Ribera A, Vela E, Garcia-Antes A, Abilleira S. Evolución del gasto en servicios sanitarios antes y después del ictus isquémico: análisis de base poblacional. Neurologia. 2019. https://doi.org/10.1016/j.nrl.2018.11.002.
Candio P, Violato M, Luengo-Fernandez R, Leal J. Cost-effectiveness of home-based stroke rehabilitation across Europe: A modelling study. Health Policy. 2022;126(3):183–9. https://doi.org/10.1016/j.healthpol.2022.01.007.
Donkor ES. Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treatment. 2018;2018:3238165. https://doi.org/10.1155/2018/3238165.
Rajsic S, Gothe H, Borba HH, Sroczynski G, Vujicic J, Toell T, Siebert U. Economic Burden of Stroke: A Systematic Review on Post-Stroke Care. Value in Health. 2019;19(7):A633. https://doi.org/10.1016/j.jval.2016.09.1649.
Dusheiko M, Gravelle H, Martin S, Rice N, Smith PC. Does better disease management in primary care reduce hospital costs? Evidence from English primary care. J Health Econ. 2011;30(5):919–32. https://doi.org/10.1016/j.jhealeco.2011.08.001.
Tawfik A, Wodchis WP, Pechlivanoglou P, et al. Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation. Appl Health Econ Health Policy. 2016;14:313–22. https://doi.org/10.1007/s40258-016-0229-2.
Li X, Tse VC, Au-Doung LW, Wong ICK, Chan EW. The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review. Europace. 2017;19(6):937–47. https://doi.org/10.1093/europace/euw093.
Sussman M, Menzin J, Lin I, et al. Impact of atrial fibrillation on stroke-related healthcare costs. J Am Heart Assoc. 2013;2(6):e000479. https://doi.org/10.1161/JAHA.113.000479.
Sociedad Española de Cardiología. Atlas del mal control de la anticoagulación en pacientes con fibrilación auricular no valvular. https://secardiologia.es/images/secciones/clinica/atlas-mal-control-anticoagulacion-INFOGRAFIA.pdf. (Accessed 23 June 2022)
Buisman LR, Rijnsburger AJ, den Hertog HM, et al. Clinical practice variation needs to be considered in cost-effectiveness analyses: a case study of patients with a recent transient ischemic attack or minor ischemic stroke. Appl Health Econ Health Policy. 2016;14:67–75. https://doi.org/10.1007/s40258-015-0167-4.
Price CI, White P, Balami J, Bhattarai N, Coughlan D, Exley C, et al. Improving emergency treatment for patients with acute stroke: the PEARS research programme, including the PASTA cluster RCT. Southampton: National Institute for Health and Care Research; 2022.
Sentinel Stroke National Audit Programme – Annual Report 2019–20. https://www.hqip.org.uk/resource/sentinel-stroke-national-audit-programme-annual-report-2019-20/#.YqNfgP3ML3g. (Accessed 5 Oct 2021)
Demaerschalk BM, Hwang HM, Leung G. US cost burden of ischemic stroke: a systematic literature review. Am J Manag Care. 2010;16(7):525–33.
Kritikou P, Vemmos K, Payne KA. In-patient hospital costs of stroke: a focused literature review. Value Health. 2014;17(7):A502. https://doi.org/10.1016/j.val.2014.08.1516.
Koopman MS, Hoving JW, van Voorst H, et al. Cost-effectiveness of CT perfusion for patients with acute ischemic stroke (CLEOPATRA)-Study protocol for a healthcare evaluation study. Eur Stroke J. 2022;7(2):188–97. https://doi.org/10.1177/23969873221092535.
Van den Berg LA, Berkhemer OA, Fransen PSS, et al. Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke. Stroke. 2022;53(3):968–75. https://doi.org/10.1161/STROKEAHA.121.034599.
Yarnoff B, Khavjou O, Elmi J, et al. Estimating Costs of Implementing Stroke Systems of Care and Data-Driven Improvements in the Paul Coverdell National Acute Stroke Program. Prev Chronic Dis. 2019;16:E134. https://doi.org/10.5888/pcd16.190061.
Balami JS, Coughlan D, White PM, et al. The cost of providing mechanical thrombectomy in the UK NHS: a micro-costing study. Clin Med (Lond). 2020;20(3):e40–5. https://doi.org/10.7861/clinmed.2019-0413.
Townsend N, Kazakiewicz D, Lucy Wright F, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19(2):133–43. https://doi.org/10.1038/s41569-021-00607-3.
Feigin VL, Abajobir AA, Abate KH, et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology. 2017;16(11):877–97. https://doi.org/10.1016/S1474-4422(17)30299-5.
Declarations of interest
Jorgina Lucas Noll reports a relationship with Government of Catalonia Agency for Administration of University and Research Grants that includes funding grants (“Doctorat Industrial 208 DI 010”) . Josep Lluis Clua Espuny reports a relationship with Primary Care Research Institute Jordi Gol that includes funding grants (GRANT PERIS 2022 4R22/031). Mar Lleixa-Fortuño has nothing to disclose. Ester Gavalda-Espelta has nothing to disclose. Lluisa Queralt-Toms has nothing to disclose. Anna Panisello-Tafalla has nothing to disclose. Misericordia Carles-Lavila has nothing to disclose.
Jorgina Lucas Noll reports a relationship with Government of Catalonia Agency for Administration of University and Research Grants that includes funding grants (“Doctorat Industrial 208 DI 010”). Josep Lluis Clua Espuny reports a relationship with Primary Care Research Institute Jordi Gol that includes funding grants (GRANT PERIS 2022 4R22/031). The rest of authors: none.
Ethics approval and consent to participate
Consent for publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1. Appendix Table 1.
Search strategy, terms and descriptors used. Appendix Table 2. Scottish Intercollegiate Guidelines Network (SIGN) grades of evidence. Appendix Figure 1. Stroke chart-flow and cost stroke organization.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Lucas-Noll, J., Clua-Espuny, J.L., Lleixà-Fortuño, M. et al. The costs associated with stroke care continuum: a systematic review. Health Econ Rev 13, 32 (2023). https://doi.org/10.1186/s13561-023-00439-6
- Acute stroke
- Costs study
- Pre-hospital pathways
- No-treatment cost